BI 1703880, a novel STimulator of INterferon Genes (STING) agonist, has demonstrated preclinical antitumor activity. As STING activation can upregulate programmed death ligand 1 and human leukocyte antigen in tumor cells, a combination of BI 1703880 and an anti-programmed cell death protein 1-antibody, such as ezabenlimab, may improve efficacy. This first-in-human phase Ia study (NCT05471856) is evaluating BI 1703880 plus ezabenlimab in patients with advanced solid tumors. The study utilizes an innovative lead-in design; all patients receive BI 1703880 monotherapy in Cycle 1 and combination therapy from Cycle 2. The primary endpoint is dose-limiting toxicities during the maximum tolerated dose evaluation period. Results will inform the future development of BI 1703880 for treatment of metastatic or recurrent malignancies.Clinical Trial number: NCT05471856.
Journal article
2025-01-01T00:00:00+00:00
21
195 - 200
5
DNA sensor, PD-1 antibody, STING, STimulator of INterferon Genes, cancer, immune checkpoint inhibitor, immunotherapy, phase I, Humans, Neoplasms, Membrane Proteins, Female, Male, Antineoplastic Combined Chemotherapy Protocols, Maximum Tolerated Dose, Middle Aged, Adult, Aged, Clinical Trials, Phase I as Topic, Treatment Outcome, STING Protein